|
3M submitted a TSCA Section 8(e) substantial risk notice to the EPA regarding preliminary findings from a toxicity study on 1-Butanesulfonamide, 1,1,2,2,3,3,4,4,4-nonafluoro-n-methyl (N-MePFBA), indicating significant reproductive effects and possible neurotoxicity in rats at high dosage
|
2003 |
AR226-1541
|
gDeNLRBwdeoKgwoXwaQ66G3O3 |
2 |
|
This document is a toxicology study report (PT02-0222) conducted by Aventis Pharma on the oral toxicity of a substance related to PFOA over a 28-day period with a subsequent 14-day recovery phase.
|
2003 |
AR226-1525
|
gay4BB67EZV26r5M7ODnY411J |
496 |
|
This document reports on a combined repeated dose toxicity study with reproduction and developmental toxicity screening for the substance T-7601 (PFOA) administered by oral gavage in Wistar rats, noting treatment-related clinical signs and mortality in the high dose group (1000 mg/kg).
|
2003 |
AR226-1542
|
zz37VOkB6J6XZOv1b91LMM7DB |
7 |
|
The document discusses an update on cancer incidence and overall mortality rates among employees and pensioners of E. I. du Pont de Nemours and Company, emphasizing the need for careful interpretation of the data in relation to employee health monitoring, but does not specifically mention PFOA or PFOS.
|
2003 |
AR226-1545
|
Evg91qVd9K6YV05eNKN04pkRn |
11 |
|
The document provides cancer incidence and mortality surveillance data for Du Pont employees at the Washington Works site from 1956-1989 and 1957-1991, respectively, generated from the company's epidemiologic surveillance program, with a recommendation for further follow-up if statistically significant excesses are found.
|
2003 |
AR226-1546
|
JNJN3KZxkJ9NjEaL41XK2B2Na |
9 |
|
The document reports on a study conducted by E.I. du Pont de Nemours and Company examining the age effect on plasma concentration of Ammonium Perfluorooctanoate in post-weaning rats following oral gavage, completed on December 15, 2003.
|
2003 |
AR226-1553
|
bBoakZzLQ9O85zwkKjdmYY0xZ |
34 |
|
This document details a pharmacokinetic study on PFOA conducted by E.I. du Pont de Nemours and Company and 3M Company, focusing on the lactational and placental transport of PFOA in rats, completed on December 19, 2003, and compliant with Good Laboratory Practice standards.
|
2003 |
AR226-1551
|
n9XQQ9zGBRBNnq1ZDge825MpG |
143 |
|
The document is a final report on an oral gavage combined repeated dose toxicity study of the test substance T-7706, which includes reproductive and developmental toxicity screening, conducted on male and female rats.
|
2003 |
AR226-1523
|
oDEL11ZE9J3Y6LodJ4grwN6Er |
769 |
|
The document is a submission from the Telomer Research Program, representing companies including DuPont and Daikin Industries, to the EPA, providing a study report on the biodegradation of 14C-labeled 8-2 Telomer B Alcohol, with a request for the report to be restricted to "read-only" status until a related manuscript is published.
|
2003 |
AR226-1639
|
0yq0aBkYpxRKdwRmKjOdwZyb |
1 |
|
The document is a submission from Katie Smythe on behalf of the Telomer Research Program, including member companies such as DuPont, to the EPA, providing a study report on the ecotoxicity of C8-2 Alcohol based on a 21-day Daphnia magna reproduction test.
|
2003 |
AR226-1642
|
MM2mX3gKrexxXZQVYj6B5aB49 |
1 |
|
The document reports on a 21-day reproduction test of Daphnia magna using 1-Decanol, 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro- (CAS RN 678-39-7) conducted according to OECD Guideline 211
|
2003 |
AR226-1643
|
NE3Yzy3EBDmgdR8NDervvJYjD |
4 |
|
The document reports on a 21-day Daphnia magna reproduction test conducted according to OECD Guideline 211 for the substance 1-Decanol, 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro, sponsored by Asahi Glass, Clariant,
|
2003 |
AR226-1644
|
nmL0mY4dd6pxRNree1VD8ER91 |
54 |
|
The document is a correspondence from R. L. Ritchey of DuPont Washington Works to Ken Westfall of USA Waste regarding the disposal of up to 9,000 tons of non-hazardous railroad soil contaminated with PAHs, noting that preliminary analysis for PFOA is included without QA/QC.
|
2003 |
AR226-1672
|
44697LdgqNZoewYwO100DO1zV |
8 |
|
The document details an air quality dispersion modeling analysis of ammonium perfluorooctanoate (C8) emissions conducted by the DuPont Fayetteville facility, outlining the methodology, emissions inventory, and meteorological data used for the assessment.
|
2003 |
AR226-1673
|
mBowDjeN3JEp6gQVqOzpNgMo0 |
6 |
|
The document outlines the modeling methodology and results for ambient air concentrations of pollutants, specifically focusing on PFOA emissions from various scrubber systems at the Shimizu Site, utilizing the Industrial Source Complex Short Term 3 (ISCST3) model.
|
2003 |
AR226-1674
|
pe5yR3y1Ywk8pRrZRvdMJ7Yzk |
11 |
|
The document is a submission to the EPA regarding a fluorosurfactant formulation used in the production of AFFF (aqueous film-forming foam) agents, provided by an unnamed company in cooperation with the Fire Fighting Foam Coalition, and includes confidential business information.
|
2002 |
AR226-1045
|
N2zD7N74Zz0y3QEKO4Nz0q8xp |
2 |
|
3M is submitting additional data on perfluorooctane sulfonates and related compounds to the EPA, including new study reports and a bibliography, as part of their ongoing dialogue regarding fluorochemicals.
|
2002 |
AR226-1051
|
EqqMZ3J3ORrXbogyNwkY34OJN |
8 |
|
The document summarizes a study on the toxicity of Ammonium Perfluoro-octanoate (APFO) conducted on Cynomolgus monkeys, revealing signs of liver and muscle toxicity at higher doses, with a specific incident of morbidity in the 3 mg/kg group, and overall findings indicating a dose-dependent increase in liver weight without clear pathological changes at lower doses.
|
2002 |
AR226-1053
|
Em8eRjRvrJ8kknDMrbbJp9vkn |
26 |
|
This is a cover page for a Fluoropolymer Manufacturers Group meeting, with no analytical content retained in the OCR.
|
2002 |
AR226-1054
|
EmdqjjRmD7j2jYBk8amb4y6Ox |
2 |
|
This document summarizes studies sponsored by 3M regarding the occurrence of perfluorooctanoate (PFOA) in environmental, dietary, and human samples, concluding that PFOA is not broadly dispersed in the environment and is typically found at low concentrations, with specific findings of PFOA detected in 18 out of 31 mink livers from Massachusetts.
|
2002 |
AR226-1055
|
JJ7pg1zZmEjm8Z1gnwmm3ERa6 |
17 |
|
The document reports the results of an acute inhalation toxicity study conducted on a mixture of perfluorinated compounds, including ammonium salts, which revealed high mortality rates in rats exposed to higher concentrations, indicating significant toxicity.
|
2002 |
AR226-1057
|
ZXBBk25L5wG2Z9QxEgergr8p |
1 |
|
The document contains comments from Rich Purdy regarding the Telomer Research Plan, specifically questioning the choice of the 8:2 telomer alcohol for testing due to its rapid metabolism to PFOA and highlighting potential deficiencies in the research approach.
|
2002 |
AR226-1058
|
gaGK369OdV4e2zgR0LzqgN1aV |
3 |
|
The Fire Fighting Foam Coalition provided the EPA with information regarding the chemistry and quantity of fluorosurfactants, specifically noting that approximately 138,000 pounds of these substances were used in the production of aqueous film-forming foam (AFFF) agents in the U.S. in 1999, primarily focusing on telomer-based AFFF agents.
|
2002 |
AR226-1065
|
89dqpKRox8aKVgBgg4LQnrZ5 |
1 |
|
The document is an updated submission from DuPont regarding the Telomer Research Program, which includes a withdrawal of the confidential business information claim for specific pages and corrections to a typographical error, intended to replace a previous version in the EPA's public record.
|
2002 |
AR226-1066
|
3JOLymn14oZbj61dwGDoBQ8JD |
34 |
|
The document is a submission from DuPont Haskell regarding the inclusion of a report titled "K-24921: Dermal Sensitization Test Buehler Method" in the AR226 and TSCA Section 8 FYI files, confirming that it contains no trade secrets or confidential business information.
|
2002 |
AR226-1067
|
82qadN6zDJ22MZLd9BOXVEXyd |
26 |
|
3M submitted a final report on a 2-year rat feeding study of N-ethyl perfluorooctanesulfonamidoethanol (CASRN 1691-99-2) to the EPA, indicating that liver effects and increased thyroid and hepatocellular adenomas were observed at the 100 ppm dose level.
|
2002 |
AR226-1068
|
XRkRGE21y83mJ88Q7dgkGNLMJ |
2 |
|
The document is an updated submission from DuPont to the U.S. EPA regarding a presentation on PFOA, clarifying that certain previously claimed confidential business information is now public and providing revised timelines and study material names.
|
2002 |
AR226-1069
|
v1GEVjx5D80NQdr3zVKdbv7zY |
36 |
|
3M submitted a final report from Covance Laboratories detailing a 2-year rat feeding study on potassium perfluorooctanesulfonate (PFOS), which found increased liver toxicity and hepatocellular adenoma incidence in male rats at higher doses.
|
2002 |
AR226-1070
|
VG9qR1ZZew7jY2Yy5RoMnQno4 |
3 |
|
The document discusses the EPA's publication of a Final Rule and a Supplemental Proposed Rule regarding the regulation of 13 discontinued perfluoroalkyl sulfonate (PFAS) chemicals and 75 additional chemicals, requiring significant new use notices for their manufacture or import after December 31, 2002, while clarifying the terminology used for PFAS and PFOS.
|
2002 |
AR226-1072
|
Ne9Nm8kkKVqNvMjoQJQM9pmLD |
2 |
|
This is a letter from the Fire Fighting Foam Coalition, signed by Executive Director Thomas A. Cortina, addressing Mr. Auer regarding issues related to firefighting foam and its environmental impact.
|
2002 |
AR226-1075
|
9JgJE6jBVRjmL0vxkLpx0z3OV |
1 |
|
The document is a memorandum from the EPA discussing a Draft Hazard Assessment of Perfluorooctanoic Acid (PFOA) and its salts, indicating that PFOA may present environmental and health concerns similar to PFOS, including persistence, potential bioaccumulation in humans, and carcinogenic effects in animals, while noting that further studies are still pending.
|
2002 |
AR226-1077
|
j2yoq8d4ZXXNkeaDdmZN6D0Q |
2 |
|
The document is a draft hazard assessment of Perfluorooctanoic Acid (PFOA) prepared by the EPA, indicating that PFOA may present environmental and health concerns similar to those of PFOS, including persistence, potential bioaccumulation in humans, and carcinogenic effects in animals, while noting that further reproductive study data are still pending.
|
2002 |
AR226-1078
|
YGxqn8qLoZ2yQrNDVvwp7b69V |
2 |
|
3M submitted a TSCA 8(e) supplemental notice to the EPA regarding draft reproduction studies on Perfluorooctanesulfonate (PFOS) in northern bobwhite and mallard ducks, indicating that while higher feed levels caused toxicity, the 10ppm group showed no adverse reproductive effects compared to controls.
|
2002 |
AR226-1080
|
gDgqmx8g05a9w7E88ODMEb3Q |
2 |
|
The document reports that the EPA has reached a consent agreement with DuPont regarding a plan to supply drinking water in response to concerns related to perfluorinated compounds.
|
2002 |
AR226-1076
|
7RqXKjz1o8oEVj6eByNVKNdno |
50 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding Ammonium Perfluorooctanoate (APFO), CAS#: 3825-26-1, highlighting statistically significant adverse effects observed in a reproduction study in rats, including decreased lactation index and delays in sexual maturation, while noting that further analysis is needed to determine causation.
|
2002 |
AR226-1081
|
J3GOQ7wrjbgRmdngBEGQjkpvZ |
1 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports on the identification of fluorochemicals, including PFOS and PFOA, in human sera and their serum half-lives, to facilitate access to previously notified information.
|
2002 |
AR226-1082
|
dY483zjdqqzXav7YOgpwNjLnG |
2 |
|
The document is a final report from 3M Company detailing a study that analyzed 645 serum samples from American Red Cross adult blood donors for the presence of fluorochemicals, finding a geometric mean concentration of PFOS at 34.9 ppb.
|
2002 |
AR226-1083
|
G51a8nEz2KeL0EeZVR8qLEZmx |
39 |
|
The document is a final report from 3M Company detailing the identification and quantitative analysis of various fluorochemicals, including PFOS and PFOA, in serum samples from elderly participants in a cognitive function study in Seattle, with a reported geometric mean concentration of PFOS at 31.0 ppb.
|
2002 |
AR226-1084
|
N2o0MDX0B6vrn28jnRr2mkG0D |
31 |
|
The document is a final report from 3M Company detailing a study that analyzed serum samples from pediatric participants in a clinical trial for group A streptococcal infections to characterize the distribution of seven fluorochemicals, including perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA).
|
2002 |
AR226-1085
|
O37b7NdoVpOdQL2R2gr3z3xDe |
48 |
|
This interim report from 3M Company details an ongoing study to determine the serum half-lives of PFOS and PFOA in human retirees from fluorochemical production plants, indicating a likely serum half-life of PFOS between 139-640 days and PFOA around one year, while addressing previous methodological concerns raised by 3M in correspondence with the U.S. EPA.
|
2002 |
AR226-1086
|
37DOprevo9gjoM899vQn0jED6 |
22 |
|
This document discusses the benchmark doses for tumors in Sprague Dawley rats fed N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), highlighting the calculation of the benchmark dose lower confidence limit (BMDL) for cancer risk assessment based on bioassay data.
|
2002 |
AR226-1089
|
omj8kx5opbqEdddVgKyqK249D |
4 |
|
The document discusses the benchmark dose (BMD) for liver tumors in Sprague Dawley rats fed Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), detailing the methodology for calculating the BMDLio and its implications for cancer risk assessment.
|
2002 |
AR226-1090
|
Vr0DDYoaNd9wxn3qzYKj6z0w |
4 |
|
3M submitted a final report to the EPA regarding a two-generation reproduction study in rats on Ammonium Perfluorooctanoate (CAS# 3825-26-1) as part of their TSCA 8(e) substantial risk notification.
|
2002 |
AR226-1091
|
kDngZVVnnDrKkzEqNpGKVGx5D |
1 |
|
The document is a draft hazard assessment by the EPA evaluating the potential health and environmental hazards associated with perfluorooctanoic acid (PFOA) and its salts, focusing on toxicology data, including a two-generation reproductive toxicity study of ammonium perfluorooctanoic acid (APFO) and related compounds.
|
2002 |
AR226-1079
|
6BgbnD3Bnvzm8mQ6r33VneOyo |
339 |
|
The document is a letter from the Society of the Plastics Industry, Inc. to the EPA, providing presentation slides from the Fluoropolymer Manufacturers Group regarding PFOA, including discussions on risk assessment, environmental distribution, exposure routes, and industry efforts to minimize environmental impact.
|
2002 |
AR226-1094
|
DaYmG5zGaewJ7GX1rZq80124 |
34 |
|
The document is a communication from the EPA regarding a corrected version of the Draft Hazard Assessment of Perfluorooctanoic Acid (PFOA) and its salts, which includes an error in the original text that has been rectified.
|
2002 |
AR226-1093
|
ZJpJEZKrbo7yoGExpoKZQqxLp |
82 |
|
3M submitted additional data to the EPA regarding perfluorooctane sulfonates, including a final report on a two-generation reproduction study of ammonium perfluorooctanoate in rats, which analyzes the effects of gestational age and body weight on reproductive outcomes.
|
2002 |
AR226-1095
|
baRG5pYnb6JxL2LdLm0ZyMbNO |
1 |
|
The document discusses the covariant analysis for study 418-020 related to sexual maturation in rats, focusing on the effects of gestational age and body weight as covariates, in the context of research conducted by Charles River Laboratories for 3M, potentially involving perfluorinated compounds.
|
2002 |
AR226-1096
|
vVQbBOY4xBy1rV5Xk4mBy2B0Z |
22 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a rat study on triphenylbenzyl phosphonium cation/N-Methyl perfluorooctanesulfonamide salt, indicating significant toxicity at higher doses and identifying a No Observable Adverse Effect Level (NOAEL) at 5 mg/kg.
|
2002 |
AR226-1097
|
ykdZdEByjoEmbDBmdwVRkZ59n |
1 |
|
3M submitted a series of reports and data to the EPA regarding perfluorooctane sulfonates (PFOS) and related compounds, including toxicity studies and health advisories, as part of their ongoing dialogue about fluorochemicals.
|
2002 |
AR226-1100
|
n9gDLmZGpzR9rRRLv20xE2qgw |
2 |
|
The document is a response from the EPA regarding a request for medical monitoring of firefighters exposed to PFOS in firefighting foam, noting that 3M was the sole producer of PFOS-based foam and has ceased production, while the EPA continues to investigate other fluorinated compounds.
|
2002 |
AR226-1099
|
xz45mYG4gmMBMGvaVk8x53M0m |
13 |
|
The Toxikon final report indicates that Ammonium Perfluorooctanoate (PFOA) did not induce mutations in the CHO/HGPRT forward mutation assay, showing no significant increase in mutant colonies compared to negative controls.
|
2002 |
AR226-1101
|
2qpOkYKOQwEZkJ5QodKxZQb7R |
29 |
|
This document establishes a Lifetime Drinking Water Health Advisory (DWHA) of 4 pg/L for perfluorooctanesulfonate (PFOS), based on EPA methodology and assumptions regarding water consumption.
|
2002 |
AR226-1105
|
6K5OqXxeBaEYoaVvjj6vdze6 |
6 |
|
The document is an analytical report from 3M Environmental Laboratory detailing the determination of the presence and concentration of Perfluorooctane Sulfonate (PFOS) in serum and liver samples of Cynomolgus monkeys as part of a medical department study (T-6295.22) completed on May 3, 2002.
|
2002 |
AR226-1103
|
6E0OvwZ6QNGq3dG0XgEMakO4 |
113 |
|
The document details a study on the acute toxicity of perfluorooctanesulfonate (PFOS) to the earthworm species Eisenia fetida, conducted using OECD Guideline No. 207, with a test substance purity of 86.9% and results analyzed for significant differences from control means.
|
2002 |
AR226-1106
|
ZBqrmepBj0jwpJyx0QOxXKzDL |
58 |
|
This document is a bibliography listing literature related to PFOS and N-EtFOSE alcohol, indexed for a July 2002 submission, including various studies and articles on the toxicity and environmental impact of these compounds.
|
2002 |
AR226-1110
|
rBE2j73Y3Q3Ln5V1LmRo2qZRe |
3 |
|
The memorandum details a meeting on August 13, 2002, between EPA officials and corporate executives from the Fluoropolymer Manufacturers Group to discuss toxicological data and human exposure levels related to perfluorooctanoic acid (PFOA), highlighting concerns about its hazards and the need for continued collaboration and clear public communication regarding these issues.
|
2002 |
AR226-1112
|
KJYV1rnxbQdGergr8n5bLKkYw |
3 |
|
This is a memorandum from the EPA's Office of Prevention, Pesticides and Toxic Substances regarding a presentation by the Fluoropolymer Group, related to the administrative record AR-226 on PFOS, PFOA, and telomers.
|
2002 |
AR226-1114
|
zb0nrByx19aDdv4mM0zYXG32R |
3 |
|
This is a letter from the Environmental, Safety and Occupational Health department discussing the risks associated with AFFF fire-fighting foam and recommending medical monitoring for firefighters exposed to PFOS.
|
2002 |
AR226-1113
|
kk5EpVdjXEaz485q0yXxwdQB |
11 |
|
This document is a request from the OECD Environment, Health and Safety Division for member countries to provide information on current or planned risk management activities regarding PFOS (Perfluorooctane Sulfonate) following a draft assessment that identified PFOS as persistent, bioaccumulative, and toxic.
|
2002 |
AR226-1115
|
gbQOM06Xkd3nNMQ9B5Ox2Q5Vq |
2 |
|
The memorandum summarizes a meeting held on August 30, 2002, between EPA toxicologists and the Fluoropolymer Manufacturers Group to discuss findings from two toxicology studies on ammonium perfluorooctanoate (APFO), where EPA recommended reanalysis of estrus cyclicity data and an analysis of implantation losses, which the industry accepted.
|
2002 |
AR226-1117
|
1J7mEYK42dDXRzBjK03Xy635 |
3 |
|
The document discusses a draft exposure data gaps discussion on PFOA, developed by the EPA at the request of the Fluoropolymer Manufacturing Group and the Telomer Research Program, highlighting concerns about PFOA risks based on human blood monitoring data and suggesting the need for a detailed lifecycle assessment of commercial activities related to PFOA.
|
2002 |
AR226-1120
|
pmLxx8YejmJEY3kQKgL9YXGMX |
4 |
|
The document is a correspondence from The Society of the Plastics Industry, Inc. (SPI) to the EPA, providing the attendee list and presentation slides from a web conference on fluoropolymer manufacturers' programs related to EPA concerns about perfluorinated compounds.
|
2002 |
AR226-1121
|
NezMoe14EbgnOZ2NnG6LVOM88 |
13 |
|
This letter from the EPA responds to questions from the OECD regarding risk management activities related to perfluorooctane sulfonate (PFOS), detailing the identification of exposure situations in the U.S. and referencing available data on PFOS exposure levels in humans and wildlife.
|
2002 |
AR226-1116
|
44YZe5rpkZvpowLeg1zKq0rEx |
42 |
|
The memorandum summarizes a September 12, 2002 conference call between the EPA and industry participants regarding data gaps on exposure issues related to perfluorooctanoic acid (PFOA) and telomer chemicals, where the industry reported on the availability and generation of relevant data.
|
2002 |
AR226-1122
|
10ZXD3q4gMG2ZwBYxqrNx1zBd |
2 |
|
This document is a correspondence from 3M to the EPA regarding the submission of raw estrous cycling data and analyses related to toxicology studies on ammonium perfluorooctanoate (APFO) as part of ongoing discussions about perfluorinated compounds.
|
2002 |
AR226-1123
|
zoxJzRx61px6rORqRDeq11zgn |
2 |
|
This document presents estrous cycling and litter observation data from a study evaluating the reproductive effects of APFO (ammonium perfluorooctanoate) on rats, detailing cycle lengths, incidence of aberrant cycles, and litter outcomes across various dose groups.
|
2002 |
AR226-1125
|
kgVn20BJ6eYg7Oyxn3dBnjMB |
4 |
|
The memorandum discusses the revision of the PFOA hazard assessment by the EPA's Office of Pollution Prevention and Toxics, highlighting new toxicological data indicating potential reproductive/developmental toxicity and unexplained low-level exposures in the general population.
|
2002 |
AR226-1127
|
7ObVX5NRBL1Nv5p3eE8G2rXMa |
2 |
|
The memorandum discusses a study comparing vaginal cycling in F1 female rats treated with 30 mg/kg of PFOA (APFO) versus control, concluding that there were no significant differences in cyclicity between the two groups.
|
2002 |
AR226-1128
|
KJXkOp4R4ZQVvZNkdN8QJEyyo |
2 |
|
The document is a communication from the EPA regarding the Revised Draft Hazard Assessment of Perfluorooctanoic Acid (PFOA) and its salts, which updates previous assessments by incorporating new studies, including a two-generation reproductive study in rats and a six-month monkey study.
|
2002 |
AR226-1130
|
k6bnyygzrajrm1oZqRDEJDxNb |
1 |
|
The document details the estrous cycle evaluation for female rats in a study on Ammonium Perfluorooctanoate (APFO), sponsored by 3M, as part of a two-generation reproduction study protocol.
|
2002 |
AR226-1124
|
O1LRN1QM2614jngv6q6gRazv1 |
43 |
|
The memorandum discusses focused statistical analyses of data related to ammonium perfluorooctanoate (APFO) and its effects on preweaning loss, following a meeting between industry representatives and EPA staff regarding findings from a study by York (2002) that reported no significant differences in various reproductive outcomes among treatment groups.
|
2002 |
AR226-1133
|
Jv87g6KmXK5oEBko5pwE0mBr |
38 |
|
The document is a revised draft hazard assessment by the U.S. Environmental Protection Agency evaluating the potential human health and environmental hazards associated with perfluorooctanoic acid (PFOA) and its salts, primarily focusing on toxicological data available as of September 2002.
|
2002 |
AR226-1131
|
6BGvoZOK5BVJnokwqL5XmX2am |
105 |
|
3M Specialty Materials submitted additional comments to the EPA regarding the Draft Hazard Assessment of PFOA and its salts, emphasizing the need to include new human health data and address specific issues related to the Cottage Grove mortality study.
|
2002 |
AR226-1134
|
R2ddBaada41m8Y67L66M61K9v |
15 |
|
The document is a communication from the EPA regarding the November 4, 2002 edition of the Revised Draft Hazard Assessment of Perfluorooctanoic Acid (PFOA) and its salts, which updates previous drafts and incorporates new studies and comments, and is part of the publicly accessible Administrative Record AR226.
|
2002 |
AR226-1135
|
wqqNzoxVNVZ6xk42OMYpjXKZd |
1 |
|
3M submitted a TSCA section 8(e) substantial risk notice to the EPA regarding findings from a toxicity study on perfluorohexane sulfonate potassium salt (PFHS), indicating adverse effects in parental male rats, including increased liver weight and thyroid changes, while no effects were observed in parental females.
|
2002 |
AR226-1138
|
3e4GoZ89VmYzKLMxab9aB4RmO |
2 |
|
The document summarizes a meeting on October 17, 2002, between EPA officials and DuPont representatives to discuss perfluorooctanoic acid (PFOA) and ammonium perfluorooctanoate (APFO), focusing on DuPont's efforts to assess PFOA exposure and pharmacokinetics related to its use in fluoropolymer manufacturing.
|
2002 |
AR226-1139
|
e1xmRrLZDnb2Q77OB6LR4g5z4 |
1 |
|
The document is a revised draft hazard assessment detailing a study that identified levels of PFOA and six other fluorochemicals in the serum of 645 American Red Cross blood donors across six U.S. regions, using high-pressure liquid chromatography for analysis.
|
2002 |
AR226-1132
|
G6wxY5qOMkXZkMjVebeJJkxYq |
302 |
|
The document is a revised draft hazard assessment by the U.S. Environmental Protection Agency evaluating the potential human health and environmental hazards associated with perfluorooctanoic acid (PFOA) and its salts, primarily focusing on toxicology data for ammonium perfluorooctanoic acid (APFO) as of October 2002.
|
2002 |
AR226-1136
|
peKXRBLYqZeXK0g2Np63M11OE |
107 |
|
The document provides an update on the Telomer Research Program (TRP) presented to the U.S. EPA, detailing the production mass balance of telomer compounds, including PFOA, and outlining ongoing studies related to toxicology, environmental fate, and potential consumer exposure routes.
|
2002 |
AR226-1141
|
QXrqyv7499MZ1arnDDZZKdwVv |
48 |
|
This is a letterhead cover page from an unspecified organization, with no analytical content retained in the OCR.
|
2002 |
AR226-1143
|
YrbDeR5eN7xKexj76YzDjz8gE |
1 |
|
This is a letter from the EPA's Office of Prevention, Pesticides and Toxic Substances dated December 9, 2002, addressed to interested parties regarding unspecified matters.
|
2002 |
AR226-1144
|
9J52d7pn6oj21wYjw28qKnMzL |
1 |
|
This is a correspondence from DuPont, dated December 4, 2002, transmitting both sanitized and confidential presentations made to the U.S. EPA during a meeting on November 25, 2002.
|
2002 |
AR226-1146
|
DMn9je5mXpgNm4QK10n1erKkQ |
1 |
|
This document is a communication from 3M to the EPA detailing their voluntary submission of data on perfluorooctane sulfonates and related compounds, including various analytical studies on fluorochemicals in human serum and plasma, with a focus on the validation of analytical methods for PFOS and PFOA.
|
2002 |
AR226-1148
|
Y9DogZZDGya9a7MNvvLKXB4jy |
2 |
|
The EPA issued a final rule establishing a significant new use rule (SNUR) for perfluoroalkyl sulfonates, including PFOSH and its salts, requiring manufacturers and importers to notify the agency 90 days prior to commencing manufacture or import due to potential hazards to human health and the environment.
|
2002 |
AR226-1145
|
YDvBQ7RRxDry1GDyvnV2kDLan |
14 |
|
This is a biodegradation study report (Revision 1) prepared by Pace Analytical Services for 3M, focusing on the biodegradation screening of telomer-type alcohols, with project initiation on August 9, 2000, and completion on September 18, 2001.
|
2002 |
AR226-1149
|
ppM2EwZ2wVgnmeX9g5kJrb0rE |
38 |
|
The document is a presentation by DuPont to the U.S. Environmental Protection Agency on November 25, 2002, detailing their product stewardship efforts and updates on the toxicology, environmental fate, and risk characterization of fluorotelomer products, including PFOA and related substances.
|
2002 |
AR226-1147
|
DMBKpV0jrYbXovebNOZaEgYvB |
65 |
|
The document discusses the collaborative efforts of OECD member countries, led by the US and UK, to assess the environmental and human health hazards of perfluorooctane sulfonate (PFOS) following 3M's decision to phase out its manufacture and use starting in 2001.
|
2002 |
AR226-1140
|
K5E8wQzJyNpXy27nLGVq9qa0 |
362 |
|
3M submitted a TSCA 8(e) notice to the EPA detailing a study that found increased levels of perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) in the liver and serum of rats after repeated dermal exposure to certain carpet protector products, although no toxicity was observed.
|
2002 |
AR226-1153
|
N2M87g5GoG1rzq98JXxz6LBkD |
2 |
|
This document appears to be a lab report detailing the analysis of various chemical components, including fluorochemicals and solvents, but the specific context and analytical results are not clearly presented due to OCR issues.
|
2002 |
AR226-1154
|
OEoZgk78ndkYakog6M2VwxOvw |
3 |
|
The Environmental Working Group's policy memo critiques the West Virginia Department of Environmental Protection's assessment of perfluorooctanoic acid (PFOA) contamination in drinking water, highlighting significant inaccuracies in the representation of PFOA's toxicity and the establishment of drinking water safety levels.
|
2002 |
AR226-1156
|
M86QvbdGMVjGQyqbYnwJz5nL |
12 |
|
The Little Hocking Water Association reported C-8 (PFOA) test results from multiple wells, with levels ranging from 0.42 to 37.1 ppb, and noted the absence of results for Test Well #4 from the February 22, 2002 sampling.
|
2002 |
AR226-1157
|
ExGNp6NNzvoMJ6dERq00Y43aV |
7 |
|
The Environmental Working Group received a letter from the Little Hocking Water Association expressing concern about C-8 (PFOA) contamination in their drinking water supply, with levels detected as high as 78.0 ppb, significantly exceeding those found in West Virginia water supplies.
|
2002 |
AR226-1158
|
n3zwyw3myOVaKrjxe2Dq7VGG |
1 |
|
This document is a letter from Robert A. Bilott to Mary Dominiak at the EPA, submitting documents related to ammonium perfluorooctanoate (PFOA, also known as C-8) for inclusion in Administrative Record 226.
|
2002 |
AR226-1159
|
3egjjjQaynBbdDO0NYgwEn7aD |
1 |
|
This is a letter from Taft, Stettinius & Hollister LLP dated April 12, 2002, addressing multiple recipients regarding the availability of over 160,000 pages of documents from DuPont related to ammonium perfluorooctanoate (C-8) and the offer to share this data with environmental agencies under a consent order.
|
2002 |
AR226-1160
|
dO88ELKNvxqY8JOwZydyMrRG |
3 |
|
The document is a study report from 3M titled "Analysis of Endogenous Fluorochemicals in Normal Pooled Human Serum and Plasma," conducted under TSCA GLP standards, which examines the presence of fluorochemicals, including PFOA and PFOS, in human serum and plasma.
|
2002 |
AR226-1151
|
Rzaee1p9KmYVGbw1J3GX0G9B |
225 |
|
This document discusses the levels of perfluorooctane sulfonate (PFOS) and related compounds found in the blood of Japanese individuals, highlighting the widespread contamination of these substances in biological media and their prevalence in wildlife globally.
|
2002 |
AR226-1279
|
7VOyx5Nv1Z3M8NdYq75eGbnB |
4 |
|
This document is a correspondence from Roberta Bilott regarding the IRIS submission for Perfluorooctanoic Acid - Ammonium Salt (C-8) related to ongoing litigation against E.I. duPont de Nemours and Company concerning contamination of drinking water supplies.
|
2002 |
AR226-1161
|
zDnxpYj39jXDXjyqokZR2qLa |
35 |
|
This document from DuPont discusses the results of C-8 (PFOA) concentration sampling in public water supplies along the Ohio River, indicating low levels detected and a subsequent reduction in sampling frequency, with quarterly monitoring continuing at three specific locations.
|
2002 |
AR226-1165
|
Nw7wGaro0xB2p8JdZjymbBvb |
6 |
|
This is a draft report detailing Ohio River water sampling results related to C-8 analyses conducted by DuPont for the Washington Works facility and the Letart landfill, as part of a multi-media Consent Order with West Virginia environmental agencies.
|
2002 |
AR226-1166
|
1Q2VLVbXN3m9N77LEyL4mrGpj |
33 |